Atherosclerotic cardiovascular disease(ASCVD)is the first cause of death for urban and rural residents in China.Atherosclerosis is a chronic vascular inflammation and the pathological basis of ASCVD,and its main reason is lipid metabolism disorder.Therefore,reducing low-density lipoprotein cholesterol has become an important approach for the prevention and treatment of ASCVD.Small interfering RNA lipid-lowering drugs are novel lipid-lowering drugs.At present,there is little evidence-based evidence and practical experience for this class of drugs.Inclisiran,the first small interfering RNA lipid-lowering drug,was approved for sale in China in August 2023.In this article,we will review the anti-atherosclerostic mechanisms of inclisiran,its combined application with other lipid-lowering drugs,and the safety and adverse effects,and thus to provide supportive evidence in the future clinical application of more small interfering RNA lipid-lowering drugs.
NETL
NSTL
万方数据
